Immune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 5, 2020
- Accepted in final form November 4, 2020
- First Published January 12, 2021.
Author Disclosures
- Shinji Ashida, MD (shinji-a{at}koto.kpu-m.ac.jp),
- Hirofumi Ochi, MD, PhD (hochi{at}m.ehime-u.ac.jp),
- Mio Hamatani, MD, PhD (kawa30{at}kuhp.kyoto-u.ac.jp),
- Chihiro Fujii, MD, PhD (chihirof{at}koto.kpu-m.ac.jp),
- Kimitoshi Kimura, MD, PhD (kimura{at}kuhp.kyoto-u.ac.jp),
- Yoichiro Okada, MD, PhD (okady{at}kuhp.kyoto-u.ac.jp),
- Yuichiro Hashi, MD (hashiu{at}kuhp.kyoto-u.ac.jp),
- Kazuyuki Kawamura, MD, PhD (kawamura.kazuyuki.tg{at}mail.hosp.go.jp),
- Hideki Ueno, MD, PhD (ueno.hideki.8e{at}kyoto-u.ac.jp),
- Ryosuke Takahashi, MD, PhD (ryosuket{at}kuhp.kyoto-u.ac.jp),
- Toshiki Mizuno, MD, PhD (mizuno{at}koto.kpu-m.ac.jp) and
- Takayuki Kondo, MD, PhD
- Shinji Ashida, MD (shinji-a{at}koto.kpu-m.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hirofumi Ochi, MD, PhD (hochi{at}m.ehime-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mio Hamatani, MD, PhD (kawa30{at}kuhp.kyoto-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chihiro Fujii, MD, PhD (chihirof{at}koto.kpu-m.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Grants from JSPS KAKENHI (Grant No. 19K16923), Lead investigator, 2019-2021
NONE
The Shimizu Foundation for Immunology and Neuroscience
NONE
NONE
NONE
NONE
NONE
NONE
- Kimitoshi Kimura, MD, PhD (kimura{at}kuhp.kyoto-u.ac.jp),
NONE
NONE
(1)Mitsubishi Tanabe Pharma Corporation, travel/speaker honoraria (2)Takeda Pharmaceutical Co. Ltd., travel/speaker honoraria (3)Biogen Idec, travel/speaker honoraria (4)Japan Blood Products Organization, travel/speaker honoraria
NONE
(1) A method of collecting data to predict good response to plasmapheresis in autoimmune diseases (only in Japan)
NONE
NONE
NONE
NONE
NONE
NONE
(1)Novartis Pharmaceuticals (2)Japan Blood Products Organization
(1)AMED (Japan), JP19ek0109382, principal investigator, 2018- 2019 (2)JSPS KAKENHI (Japan), JP18K15473, principal investigator, 2018-
NONE
(1)Fujiwara Kinen Zaidan, (2)Konishi Foundation for International Exchange, (3)Takeda Science Foundation, (4)Mochida Memorial Foundation for Medical and Pharmaceutical Research, (5)KANAE Fondation for the Promotion of Medical Science
NONE
NONE
NONE
NONE
NONE
NONE
- Yoichiro Okada, MD, PhD (okady{at}kuhp.kyoto-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yuichiro Hashi, MD (hashiu{at}kuhp.kyoto-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kazuyuki Kawamura, MD, PhD (kawamura.kazuyuki.tg{at}mail.hosp.go.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hideki Ueno, MD, PhD (ueno.hideki.8e{at}kyoto-u.ac.jp),
NONE
NONE
NONE
Frontiers in Immunology, Editorial board, since 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
EMD Serono
NIH U19-AI082715, PI of Project 1, 2019 AMED, PI, 2019, 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ryosuke Takahashi, MD, PhD (ryosuket{at}kuhp.kyoto-u.ac.jp),
(1) KAN Research Institute INC., Scientific Advisory Board (2) DAINIPPON SUMITOMO PHARMA., Scientific Advisory Board (3) Japan Agency of Medical Research and Development, Program Supervisor of a Regenerative Medicine Medicine Research Project
NONE
(1) Novartis Pharma Japan, honoraria for lectures (2) Boehringer Ingelheim Japan, honoraria for lectures (3) GlaxoSmithKline Japan, honoraria for lectures (4) Dainippon Sumitomo Pharma, honoraria for lectures (5) FP pharmaceuticals, honoraria for lectures (6) Mitsubishi Tanabe Pharma, honoraria for lectures (7) Kyowa Hakko Kirin Co., honoraria for lectures (8) Otsuka Pharmaceutical Co., honoraria for lectures
(1) Journal of Neural Transmission, Editorial Board, 11 years (2) Neurology and Clinical Neuroscience, Editorial Board, 6 years (3) Experimental Neurobiology, Editorial Board, 7 years (4) Movement Disorders, Editorial Board, 6 years (5) Molecular Brain, Editorial Board, 3 year
(1) The use of Mutant mouse of Chimaerin for drug screening (2) Drug Screening using iPS cells
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis Pharma Japan (2) Boehringer Ingelheim Japan (3) Dainippon Sumitomo Pharma (4)Eisai Pahrma
(1) Ministry of Education, Culture, Sports, Science and Technology, Japan (2) Ministry of health labor and welfare, Japan (3) Japan Agency for Medical Research and Development
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Toshiki Mizuno, MD, PhD (mizuno{at}koto.kpu-m.ac.jp) and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Takayuki Kondo, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (S.A., C.F., T.M.), Graduate School of Medical Science, Kyoto Prefectural University of Medicine; Department of Geriatric Medicine and Neurology (H.O.), Ehime University Graduate School of Medicine, Toon; Department of Neurology (M.H., R.T.), Kyoto University Graduate School of Medicine; Department of Neurology (M.H., Y.O., Y.H., T.K.), Kansai Medical University Medical Center, Osaka, Japan; Brigham and Women's Hospital (K. Kimura), Harvard Medical School, Boston, MA; Department of Neurology (K. Kawamura), National Hospital Organization Minami Kyoto Hospital; and Department of Immunology (H.U.), Kyoto University Graduate School of Medicine, Japan.
- Correspondence
Dr. Kondo takakon78{at}hotmail.com
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia GravisA Phase 2 Randomized Control TrialVera Bril, Michael Benatar, Henning Andersen et al.Neurology, November 20, 2020 -
Article
IV immunoglobulin in patients with myasthenia gravisA randomized controlled trialLorne Zinman, Eduardo Ng, Vera Bril et al.Neurology, March 12, 2007 -
Article
Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progressionMichel Varrin-Doyer, Kara L. Pekarek, Collin M. Spencer et al.Neurology: Neuroimmunology & Neuroinflammation, September 21, 2016 -
Article
Alemtuzumab long-term immunologic effectTreg suppressor function increases up to 24 monthsStefania De Mercanti, Simona Rolla, Angele Cucci et al.Neurology - Neuroimmunology Neuroinflammation, January 21, 2016